Press releases

  • Monday, 29 August 2016

    Ferring Pharmaceuticals Acquires Exclusive Licensing Rights to Condoliase from Seikagaku Corporation

    Read press release
  • Monday, 04 July 2016

    Ferring announces Phase 3 data for investigational human recombinant FSH with individualised dosing regimen at the 32nd Annual Meeting of ESHRE®

    Read press release
  • Monday, 27 June 2016

    Ferring Pharmaceuticals announces approval of new tailored dosing regimen in the PICOPREP® (sodium picosulfate, magnesium oxide, citric acid) label in MRP countries in Europe

    Read press release
  • Tuesday, 21 June 2016

    Ferring demonstrates commitment to R&D investment through expanded Innovation Grants Program

    Read press release
Archive:

Helen Gallagher

Senior Director
Corporate Communications
Tel: +41 58 301 00 51

   

Corporate Communications

Ferring International Center S.A.
Ch. de la Vergognausaz 50
CH-1162 Saint-Prex
Switzerland
Tel: +41 58 301 00 00
Fax: +41 58 301 00 10


Email for media enquiries only.
For other queries, please see our Contact page.

Headquarters

Ferring International Center S.A.
Ch. de la Vergognausaz 50
1162 Saint-Prex
Switzerland

Tel:  +41 58 301 00 00
Fax: +41 58 301 00 10

Contact

GLOBAL LOCATOR